Biomea Fusion Inc BMEA:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
after hours iconAfter Hours: Last | 04/18/24 EDT
11.16UNCH (UNCH)
Volume
6,711
Close
11.16UNCH (UNCH)
Volume
1,664,493
52 week range
8.12 - 43.69
Loading...
  • Open11.41
  • Day High11.87
  • Day Low10.95
  • Prev Close11.16
  • 52 Week High43.69
  • 52 Week High Date06/08/23
  • 52 Week Low8.12
  • 52 Week Low Date11/13/23

Key Stats

  • Market Cap400.525M
  • Shares Out35.89M
  • 10 Day Average Volume0.87M
  • Dividend-
  • Dividend Yield-
  • Beta-0.54
  • YTD % Change-23.14

KEY STATS

  • Open11.41
  • Day High11.87
  • Day Low10.95
  • Prev Close11.16
  • 52 Week High43.69
  • 52 Week High Date06/08/23
  • 52 Week Low8.12
  • 52 Week Low Date11/13/23
  • Market Cap400.525M
  • Shares Out35.89M
  • 10 Day Average Volume0.87M
  • Dividend-
  • Dividend Yield-
  • Beta-0.54
  • YTD % Change-23.14

RATIOS/PROFITABILITY

  • EPS (TTM)-3.46
  • P/E (TTM)-3.23
  • Fwd P/E (NTM)-2.87
  • EBITDA (TTM)-124.62M
  • ROE (TTM)-84.42%
  • Revenue (TTM)-
  • Gross Margin (TTM)-
  • Net Margin (TTM)-
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date08/04/2024(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Biomea Fusion Inc

 

Profile

MORE
Biomea Fusion, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery and development of oral covalent small molecules to treat patients with metabolic diseases and genetically defined cancers. A covalent small molecule is a synthetic compound that forms a permanent bond to its target protein. The Company is utilizing its proprietary FUSION System to discover, design and develop a pipeline of covalent-binding small molecule medicines...
Thomas Butler
Chairman of the Board, Chief Executive Officer, Co-Founder
Rainer Erdtmann
President, Co-Founder, Chief Operating Officer, Director
Franco Valle
Chief Financial Officer
Address
900 Middlefield Road, 4Th Floor
Redwood City, CA
94063
United States

Top Peers

SYMBOLLASTCHG%CHG
THRD
Third Harmonic Bio Inc
11.43UNCHUNCH
LBPH
Longboard Pharmaceuticals Inc
18.01UNCHUNCH
FULC
Fulcrum Therapeutics Inc
7.06UNCHUNCH
LRMR
Larimar Therapeutics Inc
6.38UNCHUNCH
LXRX
Lexicon Pharmaceuticals Inc
1.63UNCHUNCH